Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 6:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,751 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Type 2 Diabetes Mellitus Clear all
Completed Phase 4 Interventional Results available

Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes

NCT02964585
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
George Washington University
Other
Eligibility
30 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Sep 21, 2026, 6:35 PM EDT
Recruiting Not applicable Interventional

Milk for Diabetes Prevention

NCT06513026
View directory record Official record
Conditions
Lactose Intolerance, Lactose Intolerant, Lactase Persistence, Pre-Diabetes, Diabetes Mellitus, Type 2
Interventions
Lactose-Containing Milk, Lactose-Free Milk
Dietary Supplement
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 21, 2026, 6:35 PM EDT
Terminated Phase 2 Interventional

Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 Diabetes

NCT00698789
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
INCB019602, Placebo, Metformin
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
22
States / cities
Phoenix, Arizona • Tucson, Arizona • Chula Vista, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2012 · Synced Sep 21, 2026, 6:35 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans

NCT01375491
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
Doxycycline, Placebo
Drug · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 21, 2026, 6:35 PM EDT
Completed Phase 2 Interventional

A Study of Dipeptidyl-peptidase IV (DPP-IV) RO4876904 in Patients With Type 2 Diabetes.

NCT00502710
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Placebo, RO4876904
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
12
States / cities
Hot Springs, Arkansas • Concord, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Sep 21, 2026, 6:35 PM EDT
Completed Phase 3 Interventional Results available

Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes

NCT00518882
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, exenatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
61
States / cities
Birmingham, Alabama • Goodyear, Arizona • Artesia, California + 54 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Sep 21, 2026, 6:35 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Health Without Barriers/Salud Sin Barreras- Northern Colorado

NCT06822387
View directory record Official record
Conditions
Lifestyle Risk Reduction, Adolescent Health, Family Health, Cardio-metabolic Health, Mental Health, Wellness Program, Type 2 Diabetes, Obesity, Adolescent
Interventions
Mindfulness-Based Intervention, Parent Education, Physical Activity, Brief Mindfulness Intervention for Parents, Preschool Curriculum, Nutrition and Cooking Education
Behavioral
Lead sponsor
Colorado State University
Other
Eligibility
11 Years and older
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 21, 2026, 6:35 PM EDT
Completed Not applicable Interventional

Benefits of Continuous Glucose Monitoring With GEM Lifestyle Modification for Adults With Type 2 Diabetes

NCT03207893
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GEM lifestyle modification & continuous glucose monitoring, Routine Care
Behavioral · Other
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Sep 21, 2026, 6:35 PM EDT
Terminated Phase 2 Interventional

The Application of Extremely Low Level Magnetic Fields as Adjunctive Treatment for Type II Diabetes

NCT00982293
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Resonator device, Resonator device - sham
Device
Lead sponsor
pico-tesla Magnetic Therapies, LLC
Industry
Eligibility
21 Years to 80 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Littleton, Colorado
Source: ClinicalTrials.gov public record
Updated May 4, 2011 · Synced Sep 21, 2026, 6:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus

NCT04305587
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
PF-07081532, Placebo, Clopidogrel
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Anaheim, California • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2024 · Synced Sep 21, 2026, 6:35 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes

NCT07112872
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
RO7795081, Semaglutide, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
24
States / cities
Tucson, Arizona • Lake Forest, California • Rancho Cucamonga, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 21, 2026, 6:35 PM EDT
Completed Phase 3 Interventional Results available

G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes

NCT03439072
View directory record Official record
Conditions
Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia
Interventions
G-Pen, Lilly Glucagon
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
4
States / cities
Chula Vista, California • Walnut Creek, California • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Sep 21, 2026, 6:35 PM EDT
Completed Not applicable Interventional

Effect of Vitamin D Supplementation on Hemoglobin A1c in Patients With Uncontrolled Type 2 Diabetes Mellitus

NCT00985361
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Vitamin D3 2000 international units daily, Vitamin C 500mg daily
Dietary Supplement
Lead sponsor
ProMedica Health System
Other
Eligibility
21 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Sylvania, Ohio • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated May 5, 2010 · Synced Sep 21, 2026, 6:35 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy

NCT04265261
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Placebo, RG7774
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
37
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Sep 21, 2026, 6:35 PM EDT
Completed Not applicable Interventional Results available

Diabetes Data-Assisted Remission Trial (DDART)

NCT04663061
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
Medical weight loss, Diabetes education, Continuous glucose monitoring
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 21, 2026, 6:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants

NCT06293742
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
ECC5004, Midazolam, Rosuvastatin, Digoxin, Atorvastatin
Drug
Lead sponsor
Eccogene
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2024 · Synced Sep 21, 2026, 6:35 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes

NCT00838903
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
albiglutide, sitagliptin, glimepiride, metformin, placebo albiglutide, placebo sitagliptin, placebo glimepiride
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,049 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
317
States / cities
Birmingham, Alabama • Dothan, Alabama • Hueytown, Alabama + 254 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Sep 21, 2026, 6:35 PM EDT
Active, not recruiting No phase listed Observational

Intestinal Metabolic Reprogramming as a Key Mechanism of Gastric Bypass in Humans

NCT02710370
View directory record Official record
Conditions
Obesity, Diabetes Mellitus, Type 2, Endocrine System Diseases, Glucose Metabolism Disorders, Metabolic Diseases
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 21, 2026, 6:35 PM EDT
Completed Not applicable Interventional

Continuous Glucose Monitor Application After Hospital Discharge for the Improvement of Outcomes in Patients With Poorly Controlled Type 2 Diabetes and Active Cancer

NCT04938869
View directory record Official record
Conditions
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm, Type 2 Diabetes Mellitus
Interventions
Educational Intervention, Medical Device Usage and Evaluation, Survey Administration
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Sep 21, 2026, 6:35 PM EDT
Completed Not applicable Interventional

Treating Type 2 Diabetes by Reducing Postprandial Glucose Elevations: A Paradigm Shift in Lifestyle Modification

NCT03196895
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Weight reduction training, PPG training, discrete BG feedback, continuous BG feedback
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 80 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Sep 21, 2026, 6:35 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin

NCT00673231
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
13
States / cities
Fresno, California • Greenbrae, California • Roswell, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2013 · Synced Sep 21, 2026, 6:35 PM EDT
Recruiting Phase 1Phase 2 Interventional

Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye

NCT02846571
View directory record Official record
Conditions
Diabetes
Interventions
Human Pancreatic Islet Transplantation
Biological
Lead sponsor
Midhat H. Abdulreda
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 21, 2026, 6:35 PM EDT
Completed Not applicable Interventional

A Prospective, Randomized, Parallel Crossover Study Demonstrating Subject Wearability and Usability of the I-Port Injection Port

NCT00486109
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
I-Port(TM) Injection Port
Device
Lead sponsor
Patton Medical Devices
Industry
Eligibility
14 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
Atlanta, Georgia • Omaha, Nebraska • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2008 · Synced Sep 21, 2026, 6:35 PM EDT
Not listed Phase 1Phase 2 Interventional

Measurement of Eye Blood Flow and Renal Function in Healthy and Diabetic Patients

NCT01626469
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Captopril, placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Sep 21, 2026, 6:35 PM EDT